NEW YORK (GenomeWeb News) — Transgenomic yesterday said third-quarter revenues rose 6 percent as R&D spending increased 23 percent and net loss widened by nearly 25 percent.
Total receipts for the three months ended Sept. 30 rose to $5.2 million from $4.9 million year over year.
Transgenomic CEO Craig Tuttle said in a statement that the increase in revenue “reflects continued growth in our molecular diagnostics reference lab and Pharmaceutical Services businesses.”

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.